ASMBASSEMBLY BIOSCIENCES, INC.

Nasdaq assemblybio.com


$ 15.64 $ 0.34 (2.22 %)    

Friday, 21-Jun-2024 15:59:48 EDT
QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 15.64
$ 15.80
$ 0.00 x 0
$ 0.00 x 0
$ 15.52 - $ 15.85
$ 7.69 - $ 20.04
21,809
na
85.76M
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-04-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 03-08-2018 12-31-2017 10-K
27 11-01-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 03-02-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 03-12-2015 12-31-2014 10-K
39 11-17-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-announces-126m-in-equity-financings-for-the-issuance-of-634500-shares-of-its-common-stock-and-warrants-to-armistice-capital-llc

— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runw...

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-doses-first-participant-in-phase-1ab-trial-of-hsv-inhibitor-abi-5366

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interi...

 assembly-biosciences-q1-eps-166-beats-324-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-q4-eps-174-beats-288-estimate-sales-716m

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of ...

 assembly-biosciences-announces-effective-date-of-february-9-2024-for-1-for-12-reverse-stock-split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Cal...

 assembly-biosciences-on-jan-11-notified-indiana-university-that-co-decided-to-terminate-exclusive-license-agreement-dated-september-3-2023

-SEC Filing

 assembly-biosciences-provided-an-outline-of-the-anticipated-milestones-and-progress-for-its-clinical-pipeline-during-2024

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio acros...

 why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax ...

 assembly-biosciences-q3-eps-027-misses-023-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate o...